Market LIVE
Published markets; coverage varies by country
Product profile · United States

ENTRESTO

 ·  Patent Litigation & Settlement History ↓

IngredientSACUBITRIL; VALSARTAN
Application typeNDA
Application207620
Product001
Dosage formTABLET
RouteORAL
Strength24MG;26MG
Approval date2015-07-07
Marketing statusPrescription
Status event—
ApplicantNOVARTIS PHARMS CORP
Product source

Current GenericRadar decision

Year2024
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2024-05-28
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2024-05-28
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
93881342026-11-08U U-1723———
———
93881342027-05-08— ————
—2027-05-08—
88779382027-05-27DS/DP ————
———
88779382027-11-27— ————
—2027-11-27—
111351922033-08-22U U-3084———
———
95172262033-08-22U U-3084———
———
99371432033-08-22U U-3084———
———
110586672036-05-09U U-3170———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
213605 / 001FINAL_APPROVAL · FINAL_APPROVED2024-05-28—CRYSTAL PHARMACEUTICAL SUZHOU CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213676 / 001FINAL_APPROVAL · FINAL_APPROVED2024-05-28—LAURUS LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213682 / 001FINAL_APPROVAL · FINAL_APPROVED2024-05-28—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213719 / 001FINAL_APPROVAL · FINAL_APPROVED2024-07-09—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213604 / 001FINAL_APPROVAL · FINAL_APPROVED2024-08-22—TORRENT PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213680 / 001FINAL_APPROVAL · FINAL_APPROVED2024-08-30—BIOCON PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213764 / 001FINAL_APPROVAL · FINAL_APPROVED2024-09-16—ALKEM LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213728 / 001FINAL_APPROVAL · FINAL_APPROVED2024-10-16—MACLEODS PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213808 / 001FINAL_APPROVAL · FINAL_APPROVED2025-01-08—LUPIN INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213627 / 001FINAL_APPROVAL · FINAL_APPROVED2025-01-13—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213611 / 001FINAL_APPROVAL · FINAL_APPROVED2025-07-16—NOVUGEN PHARMA SDN BHDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213748 / 001FINAL_APPROVAL · FINAL_APPROVED2025-07-16—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213668 / 001FINAL_APPROVAL · FINAL_APPROVED2025-07-17—HETERO LABS LTD UNIT IIINEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219983 / 001FINAL_APPROVAL · FINAL_APPROVED2026-01-20—SOMERSET THERAPEUTICS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219946 / 001FINAL_APPROVAL · FINAL_APPROVED2026-08-04—UMEDICA LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213631 / 001FINAL_APPROVAL · FINAL_APPROVED2026-09-02—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 16 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
213605 / 001CRYSTAL PHARMACEUTICAL SUZHOU CO LTDFINAL_APPROVAL · FINAL_APPROVED2024-05-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213676 / 001LAURUS LABS LTDFINAL_APPROVAL · FINAL_APPROVED2024-05-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213682 / 001ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-05-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213719 / 001ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2024-07-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213604 / 001TORRENT PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-08-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213680 / 001BIOCON PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2024-08-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213764 / 001ALKEM LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2024-09-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213728 / 001MACLEODS PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-10-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213808 / 001LUPIN INCFINAL_APPROVAL · FINAL_APPROVED2025-01-08 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213627 / 001DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2025-01-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213611 / 001NOVUGEN PHARMA SDN BHDFINAL_APPROVAL · FINAL_APPROVED2025-07-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213748 / 001MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2025-07-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213668 / 001HETERO LABS LTD UNIT IIIFINAL_APPROVAL · FINAL_APPROVED2025-07-17 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219983 / 001SOMERSET THERAPEUTICS LLCFINAL_APPROVAL · FINAL_APPROVED2026-01-20 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219946 / 001UMEDICA LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2026-08-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213631 / 001AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-09-02 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2024-05-28TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.